DP2/25 – Alternative Life Capital: Supporting innovation in the life insurance sector
AI Analysis
The PRA's Discussion Paper 2/25 (published November 14, 2025) invites UK life insurers to provide feedback on potential regulatory reforms that would enable them to access **alternative forms of capital through risk transfer to capital markets**, outside traditional equity and debt issuance. This initiative aims to address capital constraints in the UK life insurance sector while maintaining policyholder protection and supporting long-term economic growth.
Key dates
- 14 November 2025
- – Discussion paper published
- 2026
- – PRA planned policy design and cost-benefit analysis (alongside HM Treasury work)
- 6 February 2026 Deadline
- – Deadline for stakeholder responses to DP2/25
Suggested considerations
- *For UK life insurers:
- *Assess capital needs: Evaluate whether alternative capital structures could address your firm's capital constraints, risk management objectives, or product innovation goals.
- *Prepare consultation response: Submit detailed feedback to the PRA by 6 February 2026 addressing the 15 consultation questions, particularly:
- Q12: Key risks from increased capital flexibility and mitigation approaches
- Q13: Views on balancing ease of authorisation against ongoing supervision intensity
- Q14: Potential approaches for valuing risk transfer
What changed
The PRA is considering policy reforms centered on six core principles: Capital Quality & Quantity: Alternative life capital structures must not lower the quality or quantity of capital required to support insurance risks. Risk Transfer Focus: Structures should enable patient capital investment aligned with long-term liability profiles, allowing investors to forgo immediate returns for substantial future gains. Capital Relief Priority: Alternative life capital should predominantly deliver capital relief proportionate to actual risk transfer—not balance sheet financing or illiquidity premiums. Supervisory Flexibility: The PRA is exploring whether to focus supervision on the cedant's (insurer's) recognition of risk mitigation effects rather than prescribing specific vehicle structures. V
Compliance impact
Urgency: HIGH
Who is affected
Related regulations
References
AI-generated analysis. May contain errors or omissions — verify with the original PRA source before acting. Full disclaimer.
What the PRA said
Discussion paper 2/25
Published by PRA . Read the full notice at the source for the authoritative text.